Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (391-400 of 1,137) with videos related to

Pageof 114
Sort By:
Journal of the American Heart Association|July 29, 2020
Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering TherapiesIrfan Khan, Eric D Peterson, Christopher P Cannon, et al.
The American Journal of Cardiology|October 21, 2009
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromesJeremiah P Depta, Christopher P Cannon, Gregg C Fonarow, et al.
Journal of the American College of Cardiology|October 18, 2005
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudyStephen D Wiviott, Christopher P Cannon, David A Morrow, et al.
Chest|February 7, 2001
Intravenous thrombolysis in acute myocardial infarctionE M Ohman, R A Harrington, C P Cannon, et al.
Placenta|July 7, 2015
Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14T J Kaitu'u-Lino, R Hastie, P Cannon, et al.
The American Journal of Cardiology|May 5, 2007
Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry)Benjamin A Steinberg, P Gabriel Steg, Deepak L Bhatt, et al.
Gastroenterology|October 1, 2008
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenacLoren Laine, Sean P Curtis, Michael Langman, et al.
Clinical Cardiology|February 4, 1999
Emergency department thrombolysis critical pathway reduces door-to-drug times in acute myocardial infarctionC P Cannon, E B Johnson, M Cermignani, et al.
Circulation|June 6, 2007
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndromeKausik K Ray, David A Morrow, Marc S Sabatine, et al.
European Heart Journal|February 28, 2002
Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourableF W G Leebeek, E Boersma, C P Cannon, et al.
Pageof 114

Showing results (391-400 of 1,137) with videos related to

Sort By:
Pageof 114
Journal of the American Heart Association|July 29, 2020
Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering TherapiesIrfan Khan, Eric D Peterson, Christopher P Cannon, et al.
The American Journal of Cardiology|October 21, 2009
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromesJeremiah P Depta, Christopher P Cannon, Gregg C Fonarow, et al.
Journal of the American College of Cardiology|October 18, 2005
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudyStephen D Wiviott, Christopher P Cannon, David A Morrow, et al.
Chest|February 7, 2001
Intravenous thrombolysis in acute myocardial infarctionE M Ohman, R A Harrington, C P Cannon, et al.
Placenta|July 7, 2015
Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14T J Kaitu'u-Lino, R Hastie, P Cannon, et al.
The American Journal of Cardiology|May 5, 2007
Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry)Benjamin A Steinberg, P Gabriel Steg, Deepak L Bhatt, et al.
Gastroenterology|October 1, 2008
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenacLoren Laine, Sean P Curtis, Michael Langman, et al.
Clinical Cardiology|February 4, 1999
Emergency department thrombolysis critical pathway reduces door-to-drug times in acute myocardial infarctionC P Cannon, E B Johnson, M Cermignani, et al.
Circulation|June 6, 2007
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndromeKausik K Ray, David A Morrow, Marc S Sabatine, et al.
European Heart Journal|February 28, 2002
Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourableF W G Leebeek, E Boersma, C P Cannon, et al.
Pageof 114